Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1802-1805

  Abdallah, Marie ^a   Olafisoye, Olawole ^a   Cortes, Christopher ^b   Urban, Carl ^b   Landman, David ^a   Quale, John ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NEW YORK HOSPITAL QUEENS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; ERAVACYCLINE; GENTAMICIN; MEROPENEM; TETRACYCLINE; TIGECYCLINE; 7-FLUORO-9-PYRROLIDINOACETAMIDO-6-DEMETHYL-6-DEOXYTETRACYCLINE; ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA SEQUENCE; ELECTROPORATION; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FRAMESHIFT MUTATION; GENE EXPRESSION; HOSPITAL INFECTION; IN VITRO STUDY; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE REGRESSION; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOP CODON; UNITED STATES; ACINETOBACTER INFECTIONS; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PROCEDURES;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; NEW YORK CITY; TETRACYCLINES;

EID: 84923255578     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04809-14     Document Type: Article

References (14)

1. Landman D, Bratu S, Kochar S, Panwar M, Trehan M, Doymaz M, Quale J. 2007. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae in Brooklyn, NY. J Antimicrob Chemother 60:78-82. http://dx.doi.org/10.1093/jac/dkm129.
2. Landman D, Babu E, Shah N, Kelly P, Olawole O, Backer M, Bratu S, Quale J. 2012. Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration. J Antimicrob Chemother 67:1427-1431. http://dx.doi.org/10.1093/jac/dks063.
3. Centers for Disease Control and Prevention. 2013. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rev 62: 165-170.
4. Couet W, Gregoire N, Marchand S, Mimoz O. 2012. Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect 18:30-39. http://dx.doi.org/10.1111/j.1469-0691.2011.03667.x.
5. Landman D, Georgescu C, Martin DA, Quale J. 2008. Polymyxins revisited. Clin Microbiol Rev 21:449-465. http://dx.doi.org/10.1128/CMR.00006-08.
6. Infectious Diseases Society of America. 2010. The 10×'20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 50:1081-1083. http://dx.doi.org/10.1086/652237.
7. Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH. 2013. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 57:5548-5558. http://dx.doi.org/10.1128/AAC.01288-13.
8. Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, Wilson DN, Sutcliffe JA. 2012. Target-and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 56:2559-2564. http://dx.doi.org/10.1128/AAC.06187-11.
9. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S22. Twenty-second informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward E, Brown S, Amyes SGB, Livermore DM. 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 27:351-353. http://dx.doi.org/10.1016/j.ijantimicag.2006.01.004.
11. Villa L, Feudi C, Fortini D, Garcia-Fernandez A, Carattoli A. 2014. Genomics of KPC-producing Klebsiella pneumoniae sequence type 512 clone highlights the role of RamR and ribosomal S10 protein mutations in conferring tigecycline resistance. Antimicrob Agents Chemother 58: 1707-1712. http://dx.doi.org/10.1128/AAC.01803-13.
12. Bratu S, Landman D, Martin DA, Georgescu C, Quale J. 2008. Correlation of antimicrobial resistance with β-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. Antimicrob Agents Chemother 52:2999-3005. http://dx.doi.org/10.1128/AAC.01684-07.
13. Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, Walpole SM, Horn PT. 2014. Phase 2, randomized, doubleblind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intraabdominal infections. Antimicrob Agents Chemother 58:1847-1854. http://dx.doi.org/10.1128/AAC.01614-13.
14. Connors KP, Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, Redican S, Nicolau DP. 2014. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother 58: 2113-2118. http://dx.doi.org/10.1128/AAC.02036-13.